OCALA, Fla., May 08, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma Inc.’s CEO Thomas K. Equels will be attending the 2019 Celebration of Biotechnology where he’ll meet with investors and industry representatives to discuss the company’s recent successes and plans for the future. Hemispherx is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, as well as immune-deficiency disorders.
The BioFlorida Inc. sponsored event is being held May 9 at Foundation Park, 14193 NW 119th Terrace, Alachua, Fla., 32615. Approximately 100 life sciences exhibitors and more than 500 industry professionals are expected to attend.
Equels' meetings will focus on the company’s ongoing clinical trials and programs using its flagship investigational drug Ampligen in multiple cancer types. The company recently announced significant progress in its Ampligen pancreatic cancer program and multiple Ampligen-plus-checkpoint-blockade immuno-oncology programs, including additional planned trials at major research institutes, subject to obtaining funding. Hemispherx will be studying the effect of Ampligen on nine different solid tumor types: pancreatic, ovarian, colorectal, prostate, lung, bladder, breast, melanoma and renal cell carcinoma.
See a full immuno-oncology update here: https://hemispherx.irpass.com/Hemispherx-Biopharma-Announces-Significant-Progress-in-its-Ampligen-Pancreatic-Cancer-Program-and-Mu
Learn more about the event: https://www.bioflorida.com/page/Celebration19
BioFlorida represents 6,200 establishments and research organizations in the biopharmaceuticals, medical technology, healthIT and bioagriculture sectors that collectively employ 87,000 Floridians. Members of the BioFlorida network include emerging and established life science companies, universities, research institutions, hospitals, medical centers, incubators, economic development agencies, investors and service providers.
About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, as well as immune-deficiency disorders. Hemispherx's flagship products include the Argentina-approved drug rintatolimod (trade names Ampligen® or Rintamod®) and the FDA-approved drug Alferon N Injection®. Based on results of published, peer-reviewed pre-clinical studies and clinical trials, Hemispherx believes that Ampligen® may have broad-spectrum anti-viral and anti-cancer properties. Clinical trials of Ampligen® already conducted include studies of the potential treatment of cancer patients with renal cell carcinoma and malignant melanoma. These and other potential uses will require additional clinical trials to generate the safety and effectiveness data necessary to support regulatory approval. Rintatolimod is a double-stranded RNA being developed for globally important debilitating diseases and disorders of the immune system.
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.hemispherx.net. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.
Hemispherx Biopharma, Inc.
LHA Investor Relations
Miriam Weber Miller
Senior Vice President